Venetoclax salvage therapy in relapsed/refractory multiple myeloma

被引：3
作者：
Steinhardt, Maximilian J. [1 ]
Truger, Marietta [2 ]
Bittrich, Max [1 ]
Zhou, Xiang [1 ]
Noderer, Julia [1 ]
Riedhammer, Christine [1 ]
Xiao, Xianghui [1 ]
Gawlas, Sophia [1 ]
Weis, Philipp [1 ]
Eisele, Florian [1 ]
Haferlach, Claudia [2 ]
Mersi, Julia [1 ]
Waldschmidt, Johannes [1 ]
Einsele, Hermann [1 ]
Rasche, Leo [1 ,3 ]
Kortuem, K. Martin [1 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] MLL Munich Leukemia Lab, Munich, Germany
[3] Univ Klinikum Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 03期
关键词：
DEXAMETHASONE; COMBINATION;
D O I：
10.3324/haematol.2023.283472
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：979 / 981
页数：3
相关论文
共 10 条
  • [1] Avet-Loiseau H, 1998, CANCER RES, V58, P5640
  • [2] Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
    Bahlis, Nizar J.
    Baz, Rachid
    Harrison, Simon J.
    Quach, Hang
    Ho, Shir-Jing
    Vangsted, Annette Juul
    Plesner, Torben
    Moreau, Philippe
    Gibbs, Simon D.
    Coppola, Sheryl
    Yang, Xiaoqing
    Al Masud, Abdullah
    Ross, Jeremy A.
    Bueno, Orlando
    Kaufman, Jonathan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (32) : 3602 - +
  • [3] Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma
    Basali, Diana
    Chakraborty, Rajshekhar
    Rybicki, Lisa
    Rosko, Nathaniel
    Reed, Janice
    Karam, Maryann
    Schlueter, Kristen
    Dysert, Hayley
    Kalaycio, Matt
    Valent, Jason
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (06) : 1136 - 1140
  • [4] Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
    Costa, Luciano J.
    Davies, Faith E.
    Monohan, Gregory P.
    Kovacsovics, Tibor
    Burwick, Nicholas
    Jakubowiak, Andrzej
    Kaufman, Jonathan L.
    Hong, Wan-Jen
    Dail, Monique
    Salem, Ahmed Hamed
    Yang, Xiaoqing
    Masud, Abdullah A.
    Munasinghe, Wijith
    Ross, Jeremy A.
    Bueno, Orlando F.
    Kumar, Shaji K.
    Stadtmauer, Edward A.
    [J]. BLOOD ADVANCES, 2021, 5 (19) : 3748 - 3759
  • [5] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11) : 775 - 784
  • [6] Venetoclax plus bortezomib and dexamethasone in heavily pretreated end-stage myeloma patients without t(11;14): A real-world cohort
    Jelinek, Tomas
    Popkova, Tereza
    Duras, Juraj
    Mihalyova, Jana
    Kascak, Michal
    Benkova, Katerina
    Plonkova, Hana
    Cerna, Lucie
    Koristek, Zdenek
    Simicek, Michal
    Hajek, Roman
    [J]. HEMATOLOGICAL ONCOLOGY, 2020, 38 (03) : 412 - 414
  • [7] Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
    Kumar, Shaji
    Kaufman, Jonathan L.
    Gasparetto, Cristina
    Mikhael, Joseph
    Vij, Ravi
    Pegourie, Brigitte
    Benboubker, Lofti
    Facon, Thierry
    Amiot, Martine
    Moreau, Philippe
    Punnoose, Elizabeth A.
    Alzate, Stefanie
    Dunbar, Martin
    Xu, Tu
    Agarwal, Suresh K.
    Enschede, Sari Heitner
    Leverson, Joel D.
    Ross, Jeremy A.
    Maciag, Paulo C.
    Verdugo, Maria
    Touzeau, Cyrille
    [J]. BLOOD, 2017, 130 (22) : 2401 - 2409
  • [8] Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
    Kumar, Shaji K.
    Harrison, Simon J.
    Cavo, Michele
    de la Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina
    Hungria, Vania
    Salwender, Hans
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth A.
    Hong, Wan-Jen
    Freise, Kevin J.
    Yang, Xiaoqing
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy A.
    Ward, James E.
    Maciag, Paulo C.
    Moreau, Philippe
    [J]. LANCET ONCOLOGY, 2020, 21 (12) : 1630 - 1642
  • [9] Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14)
    Nguyen, Nina
    Chaudhry, Sana
    Totiger, Tulasigeri M.
    Diaz, Robert
    Roberts, Evan
    Montoya, Skye
    Pardo, Gabriel
    Pardo, Alejandro
    Afaghani, Jumana
    Affer, Maurizio
    Jahn, Jacob
    Bradley, Terrence
    Maura, Francesco
    Kazandjian, Dickran
    Bilbao, Daniel
    Chapman, Jennifer
    Landgren, Ola
    Hoffman, James
    Taylor, Justin
    [J]. NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [10] Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
    Szita, Virag Reka
    Mikala, Gabor
    Kozma, Andras
    Fabian, Janos
    Hardi, Apor
    Alizadeh, Hussain
    Rajnics, Peter
    Rejto, Laszlo
    Szendrei, Tamas
    Varoczy, Laszlo
    Nagy, Zsolt
    Illes, Arpad
    Valyi-Nagy, Istvan
    Masszi, Tamas
    Varga, Gergely
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2022, 28
1